Peroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Overweight and obesity lead to an increased risk for metabolic disorders such as impaired glucose regulation/insulin resistance, dyslipidemia, and hypertension. Several molecular drug targets with potential to prevent or treat metabolic disorders have been revealed. Interestingly, the activation of peroxisome proliferator‐activated receptor (PPAR), which belongs to the nuclear receptor superfamily, has many beneficial clinical effects. PPAR directly modulates gene expression by binding to a specific ligand. All PPAR subtypes (α,γ, and σ) are involved in glucose metabolism, lipid metabolism, and energy balance. PPAR agonists play an important role in therapeutic aspects of metabolic disorders. However, undesired effects of the existing PPAR agonists have been reported. A great deal of recent research has focused on the discovery of new PPAR modulators with more beneficial effects and more safety without producing undesired side effects. Herein, we briefly review the roles of PPAR in metabolic disorders, the effects of PPAR modulators in metabolic disorders, and the technologies with which to discover new PPAR modulators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“PPARα was first cloned from the rodent liver in 1990 [41], and PPARβ and PPARγ were first identified in Xenopus [42].”
BackgroundBraissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“In addition, high doses of IKKβ inhibitors such as aspirin and salicylate reverse insulin resistance by sensitizing insulin signaling in obese rodents [25].”
BackgroundA transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“In addition, insulin-resistant diabetes, hyperlipidemia, and hyperphagia were observed in 11β-HSD1 transgenic mice [20].”
BackgroundMolecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“Although fatty acids could activate PPARs, PPARα activity was induced by eicosanoids [46], cabaprostacyclin [47], and nonsteroidal anti-inflammatory drugs (NSAIDs) [48].”
BackgroundContinuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. H., & Wakil, S. J. (2001) · Science · doi:10.1126/science.1056843 · Cited by 903
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641 · cited 1×
“Recent evidence indicates that PPARδ can also promote cellular lipid accumulation by increasing the expressions of genes that are involved in lipid uptake, and by repressing key genes that are involved in lipid metabolism, inflammation, atherosclerosis, obesity, fertility, and cancer [74, 75].”
Background
Cited by
Thiazolidinediones as antidiabetic agents: A critical review
Nanjan, M. J., Mohammed, M., Prashantha Kumar, B. R., & Chandrasekar, M. J. N. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.02.009 · Cited by 316
A small molecule that blocks fat synthesis by inhibiting the activation of SREBP
Kamisuki, S., Mao, Q., Abu-Elheiga, L., Gu, Z., Kugimiya, A., Kwon, Y., Shinohara, T., Kawazoe, Y., Sato, S.-I., Asakura, K., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.07.007 · Cited by 269
Peroxisome degradation in mammals: mechanisms of action, recent advances, and perspectives
Nordgren, M., Wang, B., Apanasets, O., & Fransen, M. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00145 · Cited by 67
“Agents that are frequently used to induce peroxisome proliferation in this class of animals include hypolipidemic drugs (e.g., fibrates), industrial phthalate ester plasticizers, and several types of fatty acids (Cho et al., 2008).”
Background
Metadata
- Authors
- Cho, M.-C., Lee, K., Paik, S.-G., & Yoon, D.-Y.
- Venue
- PPAR Research
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 2008
- Issue
- 1
- Pages
- 679137-679137
- ISSN
- 1687-4757 (ISSN-L)
- 1687-4765
- OpenAlex
- W2033383369
- Cited by
- 89
- References
- 15
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders. https://app.cochat.ai/papers/10.1155/2008/679137
- The paper
- Cho, M.-C., Lee, K., Paik, S.-G., & Yoon, D.-Y. (2008). Peroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Research. https://doi.org/10.1155/2008/679137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.